10398 Pacific Center Court San Diego, CA 92121 Phone: 1-877-NANOGEN www.nanogen.com Randy White, CEO NASDAQ:NGEN Overview Founded in 1993, Nanogen integrates advanced microelectronics and molecular biology into a platform technology capable of aiding in diagnosis, genomics and drug discovery. Its principal product is the NanoChip Molecular Biology Workstation. NanoChip workstations are designed to automate DNA analysis using electronically accelerated hybridization techniques to

25861 Industrial Boulevard Hayward, CA 94545 Phone: 510-670-9300 www.lynxgen.com Norman J.W. Russell, president and CEO NASDAQ:LYNX Overview Lynx Therapeutics Inc. develops and applies novel technologies for the discovery of gene expression patterns and genomic variations for use in the pharmaceutical, biotechnology and agricultural industries. Lynx’s work is based on its proprietary cloning procedure, Megaclone technology, for use in high-resolution gene expression analysis and in

3333 Vaca Valley Parkway Suite 1000 Vacaville, CA 95688 Phone: 707-446-5501 www.lsbc.com Robert L. Erwin, chairman and CEO NASDAQ:LSBC Overview Large Scale Biology Corp. focuses on the discovery, analysis, manufacture and commercialization of proteins using its two major proprietary technologies: ProGEx and Geneware. The company’s core platforms are supported with technologies in genomics, proteomics, purification sciences and molecular biology. The company’s commercial activities

1600 Faraday Avenue P.O. Box 6482 Carlsbad, CA 92008 Phone: 760-603-7200 www.invitrogen.com Lyle C. Turner, president and CEO NASDAQ:IVGN Overview Founded in 1987, Invitrogen develops, manufactures and markets research tools in kit form for biotechnology researchers and companies. The company produces products and services that simplify and improve gene cloning, gene expression and gene analysis techniques. Invitrogen’s ResGen line offers products and services for functional

Im Neuenheimer Feld 517 D-69120, Heidelberg Germany Phone: +49 6221-403-823 www.lionbioscience.com Friedrich von Bohlen, CEO NASDAQ:LEON and Neuer Markt:LIO Overview LION Bioscience AG is a bioinformatics and genomics company dedicated to providing solutions to the life science industry and accelerating drug development. The company’s products includes the SCOUT integration and analysis product lines, which provide automated methods for the analysis of gene and protein sequences

1510 - 800 West Pender Vancouver, British Columbia Canada V6C 2V6 Phone: 604-431-9314 www.idbiomed.com Anthony Holler, CEO and director NASDAQ:IDBE and TSE:IDB Overview ID Biomedical's business is focused on two areas: genomics and vaccine development. The company uses its Cycling Probe Technology to develop applications in genomics and diagnostics. That technology has been used to develop a diagnostic for antibiotic-resistant bacteria and is being licensed to genomics companies for

7600 Wisconsin Ave., Suite 1100 Bethesda, MD 20814 Phone: 240-747-4000 www.informaxinc.com Alex Titomirov, chairman and CEO NASDAQ:INMX Overview InforMax Inc. is a bioinformatics software firm designing products for drug discovery and the better understanding of disease. The company's software includes three main products: Vector NTI Suite, a desktop sequence analysis and visualization tool for scientists engaged in genomic and protein sequence research; GenoMax, a large-scale

670 Almanor Avenue Sunnyvale, CA 94086 Phone: 408-524-8100 www.hyseq.com Ted W. Love, president and CEO NASDAQ:HYSQ Overview Hyseq Inc. applies its genomics platform for programs in sequencing, discovery of genes and genetic variances linked to diseases, drug discovery and development, and development of DNA sequencing chips. Hyseq’s Sequencing by Hybridization high-throughput technology is used to accelerate DNA sequencing and gene identification. Hyseq also has established a

4355 Varsity Drive Ann Arbor, MI 48108 Phone: 734-975-4800 www.genomicsolutions.com Jeffrey S. Williams, president, CEO and director NASDAQ:GNSL Overview Formed in 1997, Genomic Solutions Inc. develops and markets instruments, software, consumables and services for analyzing genes and proteins. The company's GeneTAC Biochip System provides library creation and management, microarray production, hybridization, imaging, analysis, a full line of reagents and consumables, and research

1745 38th Street Boulder, CO 80301 Phone: 720-565-4500 www.genomica.com Teresa Ayers, director and CEO NASDAQ:GNOM (being purchased by Exelixis Inc.) Overview Founded in 1996, Genomica Corp. is a pharmacogenomics company that develops and markets software products and services to pharmaceutical, biotechnology and genomics companies. The company's tools combine clinical, epidemiology, genetic, molecular biology and biochemistry applications into a single software environment that

24 rue Royale 75008 Paris France Phone: +33 1 55 04 59 00 www.genxy.com Andr Pernet, chairman and CEO NASDAQ:GENXY Overview Genset SA, of Paris, was founded in 1989 and has the distinction of being the first biotechnology company in France to go public on both sides of the Atlantic simultaneously. It has wholly owned subsidiaries in the United States and Japan, and majority-owned subsidiaries in Singapore, Australia and Ireland. Genset focuses on generating a pipeline of drug

5 Pleasant Street Connector P.O. Box 9322 Framingham, MA 01701 Phone: 508-271-2627 www.genzyme.com Gail Maderis, president NASDAQ:GZMO Overview Formed in 1997 after Genzyme Corp. acquired PharmaGenics, Genzyme Molecular Oncology (GMO) combines its proprietary functional genomics and antigen-discovery technology platforms to develop novel cancer therapeutics from research focused on cancer vaccines, angiogenesis inhibitors and cancer pathways. GMO receives revenue primarily from

Fraunhoferstrae 20 D-82152 Martinsried/Munich Germany Phone: +49 89 85 65 26 00 www.gpc-biotech.com Bernd R. Seizinger, president and CEO Neuer Markt:GPC Overview GPC Biotech AG is focused on applying its proprietary genomic, proteomic and drug discovery technologies to accelerate drug development. This technology platform is being used to translate gene discovery into drug development, both in partnership with life science companies and internally for the development of mechanism

100 Beaver Street Waltham, MA 02453 Phone: 781-398-2300 www.genomecorp.com Steven M. Rauscher, president and CEO NASDAQ:GENE Overview Genome Therapeutics Corp. commercializes genomics-based drug discoveries for pharmaceutical, vaccine and diagnostic products. Its gene discovery program, with new initiatives in functional genomics and pharmacogenomics, identifies and characterizes human genes associated with major diseases and bacterial genes responsible for infectious diseases. The

Company Stock Price 12/31/00 Stock Price 12/31/01 Stock Price Change(%) Shares Out (M)* Mkt. Cap. (M)** 3-Dimensional Pharmaceuticals Inc. (Nasdaq:DDDP) 14.8125 8.4900 -42.7 22.0 186.7 Aclara BioSciences Inc. (Nasdaq:ACLA) 10.8750 5.0700 -53.4 35.8 181.4 Affymetrix Inc. (Nasdaq:AFFX) 74.4375 37.7500 -49.3 57.9 2,187.2 Agilent Technologies Inc. (NYSE:A) 54.7500 28.5100 -47.9 460.6 13,132.8 Applied Molecular Evolution Inc. (Nasdaq:AMEV) 17.0625 12.3100 -27.9 23.6

West Coast Editor In tightened financial times such as those that beset biotechnology entering 2002, finding cash became even more “a matter of life and death” than usual. It was especially true for genomics firms, as the glow conferred upon them by the mapping of the human genome had begun to fade. Hello, venture capital. Always a trusted source of money for fledgling biotechnology firms, VC may turn out, as the industry becomes more mature, to be a savior for genomics companies whose

West Coast Editor When, near the end of 2001, Millennium Pharmaceuticals Inc. and COR Therapeutics Inc. merged in a stock-swap deal valued at about $2 billion, observers hailed the event not only as the largest biotechnology-biotechnology merger in history, but also as one that said plenty about genomics and said it loudly. Not that most folks didn’t already get the message. Millennium, with targets galore, found itself in serious need of products. Investor glee over the mapping of the human

West Coast Editor It almost sounded like a hedge bet. When business leaders and their hired scientists latched onto the word “proteomics,” trumpeting that the more refined field of research would push genomics past the point where (at least in the view of many investors) it had become stalled, anyone might have been forgiven for suspecting desperation. Times had grown hard for genomics. By 2002, at the year’s bellwether JPMorgan H&Q Healthcare Conference in San Francisco in January, no less

West Coast Editor In the collective mind of the lesser-educated sector of the populace, the genomics revolution means a chance for power-crazed scientists to deploy new DNA data plus cloning technology to manufacture (among other things) improved human beings: disease-resistant humans, surely, but also those with perhaps more intelligence, stronger humans, maybe even “super” beings. Science fiction dies hard. What’s more, religious and moral leaders can be reluctant to let go of their constant